NomanAS,KoideN,HassanF,I-E-KhudaI,DagvadorjJ,TumurkhuuG, 2009.Thalidomide inhibits lipopolysaccharide - induced tumor necrosis factor-alpha production via downregulation of My D88 expression,Innate Immun 15 33 -41
Eleutherakis-PapaiakovouV,BamiasA,DimopoulosMA, 2004.Thalidomide in cancer medicine,Ann Oncol 15 1151 -60
HanZX,XuJ,WangHM,MaJ,SunX,DuXP, 2014.Antiemetic role of thalidomide in a rat model of cisplatin-induced emesis,Cell Biochem Biophys 70 361 -5
MillerAB,HoogstratenB,StaquetM,WinklerA, 1981.Reporting results of cancer treatment,Cancer 47 207 -14
SanmukhaniJJ,PawarP,MittalR, 2014.Ramosetron hydrochloride for the prevention of cancer chemotherapy induced nausea and vomiting: The Indian experience,South Asian J Cancer 3 132 -7
BroderMS,FariaC,PowersA,SunderjiJ,CherepanovD., 2014.The impact of 5-HT3RA use on cost and utilization in patients with chemotherapy-induced nausea and vomiting: Systematic Review of the Literature,Am Health Drug Benefits 7 171 -82
GrunbergSM,DeusonRR,MavrosP,GelingO,HansenM,CrucianiG, 2004.Incidence of chemotherapy-induced nausea and vomiting after modern antiemetics,Cancer 100 2261 -8
JordanK,SippelC,SchmollHJ, 2007.Guidelines for antiemetie treatment of chemotherapy-induced nausea and vomiting: Past, present, and future recommendations,Oncologist 12 1143 -50
PoonKS,UnMK,LowXH,CheungYT,YapKY,ChanA, 2013.Impact of cancer-related fatigue on chemotherapy-induced nausea and vomiting in Asian cancer patients,Pharmacoepidem Dr S 22 1345 -51
YasuiK,KobayashiN,YamazakiT,AgematsuK., 2005.Thalidomide as an immunotherapeutic agent: The effects on neutrophilmediated inflammation,Curr Pharm Des 11 395 -401
LeeSM,RuddR,WollPJ,OttensmeierC,GilliganD,PriceA, 2005.Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and carboplatin in advanced non-small-cell lung cancer,J Clin Oncol 27 5248 -54
LeeSM,WollPJ,RuddR,FerryD,O'BrienM,MiddletonG, 2009.Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: A randomized, doubleblind, placebo-controlled trial,J Natl Cancer Inst 101 1049 -57
WatanabeR,TokuhiraM,KizakiM., 2013.Current approaches for the treatment of multiple myeloma,Int J Hematol 97 333 -44
HeskethPJ,Van BelleS,AaproM,TattersallFD,NaylorRJ,HargreavesR, 2003.Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists,Eur J Cancer 39 1074 -80